LSE:SNG (Synairgen plc)

About SNG

FTSE AIM 100 index member Synairgen is a biotech company, which was founded in 2003 and pioneered research using ex-vivo models. Using these models, which use cells collected from patients with a disease, Synairgen has developed two candidate treatments. The first is a Lysyl Oxidase-like 2 enzyme (LOXL2) inhibitor, which has been out-licensed to Australia-based pharmaceutical company Pharmaxis for development. The second is an inhaled interferon-beta (IFN-β) designated SNG001. AstraZeneca licensed SNG001 to investigate its potential for treating chronic lung conditions like Asthma and Chronic Obstructive Pulmonary Disease (COPD) but returned all rights back to Synairgen in 2017. Recently, the potential for SNG001 as a treatment for COVID-19 and other severe lung infections has been investigated all the way to a phase three clinical trial. However, it was announced on 21 February 2022 that SNG001 failed to meet its primary or key secondary endpoints as a treatment for COVID-19 in a hospital setting. Data from a phase two clinical trial investigating SNG001 in the home-based based treatment of COVID-19 is still awaited. Revenue generation has been sporadic at Synairgen, and profits have been made in only one of the last five fiscal years. In 2017 £5.03m was paid by to Synairgen by Pharmaxis as consideration for the change in terms to them assuming all future development, licensing, and financing responsibilities for the LOXL2 inhibitor. The 2017 revenue transferred into a £1.76m profit for Synairgen. A further £0.11m was received in 2018 for service work relating to the LOXL2 inhibitor program. Synairgen is set to receive a 17% royalty on all future LOXL2 inhibitor sales. However, developmental progress has stalled at the phase two clinical trial phase for lung fibrotic conditions, and Pharmaxis is now exploring the role of the LOXL2 inhibitor in the treatment of chronic kidney disease. Astrazeneca paid Synairgen £4.35m to license SNG001 in 2014 and a further £0.03m for related service work in 2015. Prior to this Pfizer a collaboration over SNG001 with Pfizer in 2011 yielded £0.16m in revenue, but nothing else. Synairgen remains a developmental biotech company, without a licensed product on the market.
  • Frequently Asked Questions

    Synairgen makes its annual accounts up to the 31 December of each year.

    As per the 2020 annual report, Synairgen’s directors feel the groups model is to generate value through capital growth rather than payment of dividends. No dividend was proposed in the 2020 annual report nor the 2021 Interim report. Although the analyst consensus — which is from a single broker — is for dividends to be paid in the 2021 and 2022 fiscal years of 1.99p and 4.97p per share respectively, this fool feels this is unlikely.

    Unlikely. No revenue has been reported since 2018, which related to the LOXL2 inhibitor program, and although it is involved in a phase two clinical trial, assuming it gets though this and all the way to market, any royalty income would be years away. A licensing agreement for SNG001 was a real possibility if the compound demonstrated success in its phase three clinical trial for hospital-based treatment of COVID-19, however, this trial was unsuccessful.

    Synairgen plc (LSE: SNG) Latest News

    Investing Articles

    What’s next for the Synairgen (LON: SNG) share price?

    The Synairgen share price collapsed in February after a clinical trial failure. But the company is looking towards long-term Covid…

    Read more »

    Investing Articles

    The Synairgen share price crashes again as US study is halted

    Synairgen's share price has slumped once more following fresh bad news for its SNG001 asset. Here's what we need to…

    Read more »

    Investing Articles

    The Synairgen share price jumps! Should I buy the stock?

    As the company's coronavirus treatment moves through trial phases, this Fool explains why he thinks the Synairgen share price looks…

    Read more »

    Investing Articles

    The Synairgen (SNG) share price tanks 20% on earnings. What happened?

    The Synairgen (LON:SNG) share price dropped by double-digits, despite the firm making key progress in clinical trials. Is this a…

    Read more »

    Investing Articles

    What’s going on with the Synairgen share price?

    The Synairgen share price has been on a wild ride, but that could be about to change as the company's…

    Read more »

    Investing Articles

    Hargreaves Lansdown investors are buying Synairgen shares. Should I buy too?

    Synairgen shares have been volatile. But should I buy now? This Fool takes a closer look at the company’s recent…

    Read more »

    Investing Articles

    Can the Synairgen share price continue to surge?

    The Synairgen share price has nearly doubled in two weeks. Zaven Boyrazian investigates what’s causing this growth and whether it…

    Read more »

    Investing Articles

    I think this AIM stock has bags of potential

    This AIM stock has been falling recently. But I think this is a buying opportunity. Here’s my view on the…

    Read more »

    Investing Articles

    The Synairgen share price slumps! Here’s what I’d do now

    The Synairgen share price has slumped following the publication of its latest trial results. This Fool isn't planning to buy…

    Read more »

    Coronavirus written newspaper close up shot to the text.
    Investing Articles

    UK small-cap shares: 2 Covid-19-related stocks I’d buy right now

    These two Covid-19 related UK small-cap shares are my favourites right now. Here’s why I’d buy.

    Read more »

    Investing Articles

    The Synairgen share price is up 680% in a year! Should I buy now?

    The Synairgen share price is exploding, as its new drug shows positive results. Is this a sign to buy? Zaven…

    Read more »

    Investing Articles

    The Synairgen share price: here’s why I’d buy and hold this stock

    The Synairgen share price has gained over 800% in the past year. With a potentially effective Covid treatment, I think…

    Read more »